IPM Take
Alzheimer’s research needs biomarkers. Patients need more than biomarkers.
A change in tau, amyloid or inflammatory signalling can be scientifically useful. It can help decide whether a programme deserves a larger trial. But it is not the same as preserving memory, delaying loss of independence or giving families more time with the person they know.
PrimeC’s eight-participant study is not a breakthrough. It is a test of whether the next study can be designed honestly enough to find one.
Executive Summary
NeuroSense reported exploratory biomarker findings from its Phase 2 RoAD proof-of-concept study of PrimeC in Alzheimer’s disease. The randomised, double-blind, placebo-controlled study enrolled eight participants at Rambam Health Care Campus in Haifa, Israel.
The company reported that three participants completed 12 months of follow-up with cerebrospinal-fluid and plasma samples collected at three timepoints. It described changes in tau, amyloid-beta, alpha-synuclein, TDP-43 and biomarkers linked to oxidative stress and inflammation as directionally consistent with PrimeC’s proposed mechanism.
This is not evidence of clinical benefit. The company itself describes the study as small and exploratory, with clinical outcome measures descriptive by design. The public update does not demonstrate improved cognition, preserved daily functioning or slowed disease progression.
Why it matters
- Patients / advocates: Small biomarker studies can generate hope quickly. The evidence standard must remain tied to outcomes that shape everyday life.
- Clinicians: A biological signal can be worth pursuing, but it should not be confused with evidence that a treatment changes cognitive or functional decline.
- Researchers / regulators: The next study needs enough participants, transparent endpoints and a credible link between biomarker movement and patient-relevant benefit.
Alzheimer’s research has learned how easy it is to mistake movement for progress.
A biomarker changes. A scan looks better. A molecular pathway appears to respond. Those findings can matter, especially in a disease as biologically complex as Alzheimer’s. But they become clinically meaningful only when they help people remember longer, function better and stay independent for more time.
NeuroSense’s PrimeC update sits firmly at the beginning of that chain.
The RoAD study enrolled eight people. Only three participants completed 12 months of follow-up with repeated cerebrospinal-fluid and plasma samples. The company reports biomarker changes involving tau, amyloid-beta and proteins associated with other neurodegenerative processes, alongside markers of oxidative stress and inflammation.
That is a legitimate early biological signal. It is not an answer.
With such a small dataset, the study cannot establish whether the findings are reproducible, whether they apply across different biological profiles or stages of disease, or whether they translate into a difference patients and caregivers would recognise in everyday life.
The responsible next step is not louder language. It is a stronger trial.
That means a study large enough to test cognition and daily function, designed around patient-relevant outcomes, with transparent safety reporting and a clear plan to show that target engagement is more than an elegant laboratory observation.
Alzheimer’s does not need another mechanism with a persuasive slide deck. It needs evidence that survives contact with real lives.
